Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON
Wuyts W, Bonella F, Chaudhuri N, Varone F, Antin-Ozerkis D, Song J, Miede C, Dumistracel M, Coeck C, Cottin V. Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON. Lung 2025, 203: 25. PMID: 39789408, PMCID: PMC11717875, DOI: 10.1007/s00408-024-00778-z.Peer-Reviewed Original ResearchConceptsProgressive pulmonary fibrosisForced vital capacityAdverse eventsSafety profilePulmonary fibrosisConclusionThe safety profileDiscontinuation of nintedanibExposure to nintedanibSafety of nintedanibOpen-label extensionBaseline to weekFrequent adverse eventsFatal adverse eventsLong-term treatmentLonger-term treatmentNintedanib groupGastrointestinal eventsINBUILD trialNintedanibMethodsAdverse eventsModerate severityPatientsContinuous treatmentVital capacityINBUILD
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply